Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | APP | P05067 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TLR4 | O00206 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23720 | 0.89 | MAOB (0.60) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL22875 | 0.87 | MAOB (0.68) | MAOBAPPNPC1RAB9ABCHE | |
| SCHEMBL22316 | 0.83 | MAOB (0.66) | MAOBSMPD1BCHESPHK2 | |
| SCHEMBL23989 | 0.82 | MAOB (0.60) | MAOBAPPSMPD1TLR4TLR2 | |
| SCHEMBL4700934 | 0.80 | APP (0.68) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL12183014 | 0.80 | MAOB (0.73) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL6670891 | 0.79 | MAOB (0.62) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL13462938 | 0.79 | MAOB (0.65) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL18614323 | 0.79 | NPC1 (0.61) | MAOBAPPNPC1RAB9ATDP1 | |
| SCHEMBL18614324 | 0.79 | NPC1 (0.61) | MAOBAPPNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703700-B2 | Bimacrocylic HCV NS3 protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2432318-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | Sequoia Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2010135748-A1 | BIMACROCYCLIC HCV NS3 PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | MAOB 1776/4885APP 3680/4885NPC1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.